HIV Treatment Bulletin - Vol. 7, No. 7/8, July/August 2006
Polly Clayden, HIV i-Base

A group of women who had received single dose nevirapine in the HIVNET 012 trial were enrolled in a long-term (up to five years) follow-up study.

Tamara Flys and coworkers from John Hopkins, analysed plasma samples from 184 of these women. The group included 39 women who were re-exposed to single dose nevirapine in one or two subsequent pregnancies. The LigAmp sensitive and quantitative point mutation assay (cutoff: 0.5% K103N) was used to detect the K103N mutation.

The authors reported a cumulative percentage of women with undetectable K103N of 58.6% by 6–8 weeks, 85.2% by 2 years, 92.1% by 3 years, 99.1% by 4 years, and 99.1% by 5 years among women receiving only single dose nevirapine in one pregnancy.

They found that the rate of “fading” of detectable K103N containing variants was slower in women with subtype D than A.

In multivariate analysis, sub types (D versus. A, HR: 0.50, 95% CI: 0.33–0.76, p=0.0005) and pre-nevirapine viral load (per log increase, HR: 0.63, 95% CI: 0.48–0.83, p=0.0007), were independently associated with slower fading, while baseline CD4 cell count was not.

Of the 39 women who received single dose nevirapine for subsequent pregnancies during the follow-up study, most had undetectable K103N within a year of re-exposure.

They also found that when K103N was detected, it was present at low levels, and “faded” from detection within 1 year of additional follow-up.

The authors concluded that K103N was undetectable in plasma from most women within 6–8 weeks of receiving single dose nevirapine in pregnancy, and in plasma from all evaluable women within 4 years. This included women who were re-exposed to single dose nevirapine in a subsequent pregnancy during the follow-up period. They noted, “K103N-containing variants persisted longer in women with subtype D and in women with higher baseline viral loads.”

Ref: Flys TS, Mwatha A, Donnell D et al. Fading of K103N-containing HIV-1 variants after initial and repeated exposure to single dose nevirapine for prevention of HIV-1 mother-to-child transmission (HIVNET 012). Antivir Ther. 2006, 11:S54 (abstract no. 46).

2006-07-10
IB060707-08

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.